The key components of therapy that affect the success rate are:
the optimal duration of therapy (48 or 24 weeks depending on
the viral genotype), the need for different regimens for patients
with G1/4 versus G2/3 infections, the appropriate doses of both
PegIFN and RBV and the effective management of the treatmentassociated
side effects (Ferenci 2008).
Antiviral Therapy: The Basics | 21
Treatment interruption due to AEs are more frequent in
patients receiving PegIFN/RBV for the longer duration of 48
weeks.
All studies show the importance of adherence (McHutchison
2002) using the 80/80/80 rule (patients who took more than 80%
of their prescribed IFN, more than 80% of their prescribed RBV,
and are treated for more than 80% of the planned treatment
duration). Adherence seems to be influenced by several patients‘
baseline characteristics: HIV coinfection; previous HCV
treatment regimen; use of illicit drugs.
the optimal duration of therapy (48 or 24 weeks depending on
the viral genotype), the need for different regimens for patients
with G1/4 versus G2/3 infections, the appropriate doses of both
PegIFN and RBV and the effective management of the treatmentassociated
side effects (Ferenci 2008).
Antiviral Therapy: The Basics | 21
Treatment interruption due to AEs are more frequent in
patients receiving PegIFN/RBV for the longer duration of 48
weeks.
All studies show the importance of adherence (McHutchison
2002) using the 80/80/80 rule (patients who took more than 80%
of their prescribed IFN, more than 80% of their prescribed RBV,
and are treated for more than 80% of the planned treatment
duration). Adherence seems to be influenced by several patients‘
baseline characteristics: HIV coinfection; previous HCV
treatment regimen; use of illicit drugs.
No comments:
Post a Comment